Research Article
Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
Table 4
Dynamics of body mass index and glycosylated haemoglobin in exenatide and liraglutide groups.
| | Therapy | BMI at baseline | BMI after 24 weeks | BMI reduction | Mean reduction of initial (%) | HbA1c at baseline | HbA1c after 24 weeks | HbA1c reduction | Mean reduction of initial (%) |
| | Exenatide, | 42.8 | 40.6 | 2.2 | 5.4 | 8.8 | 7.8 | 1.0 | 1.2 | | Liraglutide, | 40.1 | 37.6 | 2.5 | 4.0 | 8.3 | 7.2 | 1.1 | 0.9 | | -level | | | | 0.256 | | | | 0.403 |
|
|
